Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 367 participants.

Also called NCT06415773

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 367 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06415773
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06415773. Randomized; double masking; primary purpose treatment. Start 2024-06-04 (actual); primary completion 2025-06-13 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Acronym
HARMONY
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
HTD1801
Intervention (Drug)
Dapagliflozin
Lead sponsor
Shenzhen HighTide Biopharmaceutical Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06415773
Content hash
b5a4b985f7df987f4408731c9f5b34ef416d10fdaeaf38d659517df80eb22032